Three days full of meetings with new partners of prestigious local hospitals, seminars of presentation and insights dedicated to Hilterapia® and MLS®. These have been the goals of the ASAlaser’s mission in Saudi Arabia, a country where the company is already present through its distributor Rehab Al-Safwa Est.
May 19: ASA’s therapies in the Riyadh hospitals
The attention of the hospitals for ASAlaser’s therapy is increasingly strong. One-to-one meetings with medical representatives of some of the most important hospitals ("Specialized Medical Center Hospital", "Security Force Hospital" "Al Hamman Hospital" and "Saudi German Hospital") in Riyadh have been scheduled to present and also to formalize the adoption of Hilterapia® and MLS®.
May 20: space to presentations
Time for seminars. In collaboration with the local dealer, the specificities and the strengths of ASAlaser’s therapies have been presented to 20 directors of physical therapy/rehab departments of centers designated by the Ministry of Health (MOH). The meeting has been useful not only to emphasize the characteristics of Hilterapia® and to explain concepts that determine its uniqueness (Global Approach), but also to tighten the relationship with the audience.
May 21: focus on research
The three main hospitals in Jeddah - "King Fahd General Hospital", "King Fahd Military Hospital" and "Jeddah National Hospital" - have been visited and a presentation with focus on the therapeutic solutions at the Crown Plaza Hotel have been held with over 70 participants. The day has ended with an important meeting for the development of new research dedicated to Hilterapia®. «We have had a confrontation with Dr. Ehab Abdel Kafy and Dr. Mohamed Salah of Umm al-Qura University - Physiotherapy Department - explains Lucio Zaghetto, ASAlaser’s CEO. They are available to become scientific references for the Middle East and to give shape to a scientific hub on the model of our ASAcampus division. With this goal, a meeting directly in Florence with our researchers has been scheduled». The two doctors have already written and published some research dedicated to Hilterapia® in the scientific journal Energy for Health created by ASAcampus.
«This meeting has confirmed our expectation. We have achieved all the goals, and we have also confirmed once again the validity, innovation and excellence of the scientific basis of our therapeutic solutions. Thanks to the very receptive local market - concludes Roberto Terruzzi, ASAlaser’s Area Manager - we have been having the opportunity also to open the way to the dental field for the next months». Great enthusiasm also in the words of Dr. Hassan, Rehab Al-Safwa Est.’s CEO: «Working together for three intensive days allowed us to retain our customers, to increase the opportunities of new distribution agreements for Hilterapia® and also to strengthen the bond between our two teams».
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.